Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

The ACHIEVE-1 trial was a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of orforglipron — the first oral small-molecule (non-peptide) GLP-1 receptor agonist in development — in adults with early-stage type 2 diabetes, treated only with diet and exercise. Participants were randomized into four groups (placebo or orforglipron 3, 12, or 36 mg) for daily oral treatment over 40 weeks, with baseline HbA1c between 7.0% and 9.5% and BMI >=23.

The primary endpoint was HbA1c reduction at 40 weeks, with dose-dependent and statistically significant results:

• HbA1c reduction: -1.24% (3 mg), -1.48% (12 mg), -1.48% (36 mg) vs. -0.41% with placebo
• 65-75% of patients achieved HbA1c <7.0% on active doses vs. ~17% with placebo
• Weight loss: -4.5% (3 mg), -5.8% (12 mg), -7.6% (36 mg) vs. -1.7% with placebo
• Significant reductions in systolic blood pressure and non-HDL cholesterol

The safety profile was consistent with other GLP-1 agonists, with mild-to-moderate gastrointestinal events (nausea, diarrhea, constipation) being most common, mainly during dose escalation. Discontinuation due to adverse events occurred in 4.4-7.8% of patients on orforglipron vs. 1.4% with placebo. There were no cases of severe hypoglycemia.

Orforglipron represents a milestone in the development of oral GLP-1s: as a small (non-peptide) molecule, it can be administered without the food restrictions of oral semaglutide and has scalable manufacturing. The ACHIEVE-1 results, published in June 2025, positioned orforglipron as a potential first oral small-molecule GLP-1 to reach the market, with regulatory submissions anticipated for 2025-2026.